Evotec’s end-to-end integrated research and development platform will be able to advance drug discovery for two drug targets which is why it has joined forces with the Crohn’s & Colitis Foundation.
The development of small molecule antivirals that target viral RNA in Henipaviruses will benefit from a $1.7million grant from Open Philanthropy, a philanthropic funder prioritizing global health and wellbeing.
The global drug discovery market is expected to reach $68bn in 2028, according to a Visiongain report, with revenue gains driven by flexibility, agility, and the ability to innovate, says Evotec executive.
Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Evotec are among the top companies with “AI-friendly” CEOs, according to a report, which suggests that these businesses will prosper driven by a more effective application of AI.
Evotec AG is partnering with the Mark Foundation for Cancer Research to discover and develop first-in-class therapeutics in oncology using its new drug discovery platform.
Evotec is partnering with a global non-profit research group to develop a pipeline of novel antibiotics after integrating Sanofi’s infectious disease unit last year.
Evotec and Immuneering are combining iPSC and AI technologies through a research collaboration to discover novel small molecules for rare hereditary metabolic diseases.
Evotec AG and Ferring Pharmaceuticals are collaborating to discover and develop new small molecule therapies for the treatment of fertility and gynaecological conditions.
Evotec and Almirall are using a novel approach to disrupt cell signaling to discover and develop first-in-class therapeutics targeting dermatology diseases.
The joint drug discovery project announced yesterday will combine Centogene’s genetic testing service offerings with Evotec's iPSC platform and drug discovery capabilities.
Evotec and Fraunhofer IME-SP have signed a strategic collaboration to advance Evotec’s patient-derived iPSC platform and subsequent drug discovery projects.
Following an €8M Series A fundraising round by Eternygen GmBh, the German CRO Evotec AG will help get the virtual biotech’s metabolic disease inhibitor programme to preclinical trials.
With a flurry of recent deals tied to Sanofi and a string of other collaborations, Germany’s Evotec is seeing a steep rise in revenues from its contract research division and it expects that growth to continue.
With a small pipeline of clinical candidates, as well as R&D partnerships with top Big Pharma companies paying for those partnerships, Evotec could be in a position to re-define what it means to be an outsourcing partner.
The strategic partnership comes with Sanofi providing €250m to Evotec, including €40m upfront, as part of efforts to discover new drug candidates, including in the area of oncology, and specifically at Sanofi’s R&D site in Toulouse, France.
Evotec and Second Genome have agreed to partner in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases.
German CRO Evotec AG and Padlock Therapeutics have successfully completed an initial goal in developing inhibitors of protein-arginine deiminases (PADs) and have further extended their collaboration through March 2017.
Contract drug developer Evotec AG has achieved multiple milestones resulting in €8m ($9.8m) in revenue thanks to its collaborations with Bayer and Janssen Pharmaceuticals.
Evotec and Sanofi have entered into exclusive negotiations for a major strategic partnership that will include a €250m ($310m) minimum guaranteed commitment from Sanofi over the next five years.
Evotec has partnered with Shire to develop inhibitors against Fabry’s disease and says such collaborations will grow as Big Pharma increasingly looks towards rare diseases.
CRO Evotec AG will help Debiopharm identify and develop novel compounds with the potential to treat multiple forms of solid tumours and leukaemias with defined genetic alterations under a collabortation announced today.
Evotec AG has bought an asset management company that specialises in bringing academic discovery and development innovations to the attention of pharma and biopharma sponsors.
By acquiring a stake in India-based RSIPL Evotec believes it can offer clients quicker drug development services, an important aspect of coping with attrition, because larger teams of chemists are available in emerging markets.
Anglo-German firm Evotec is taking its fragment-based drug
discovery (FBDD) services a step further with the launch today of a
new innovation centre for FBDD.
Evotec is willing to accept significant losses, at least in the
short term, as it moves from being solely a service provider, to
having its own drug development programme as well.
PerkinElmer (PE) has continued its growth in the advanced cellular
sciences sector, with the completed acquisitions of Euroscreen
Products and Evotec Technologies.
Evotec and CHDI have formed a strategic partnership, which aims to
research and develop treatments for Huntington Disease (HD), a
genetic disorder that causes programmed degeneration of brain cells
and loss of intellectual faculties.
German biotech company Evotec OAI boosted its third quarter
revenues by 18 per cent to €19 million, despite the difficult
operating environment for companies supplying drug discovery
technologies, continuing its recovery from a weak...
Anglo-German company Evotec has reorganised its pharmaceutical
development services business by integrating its ProPharma
subsidiary, based in Scotland, into a new structure alongside its
in-house activities.
Germany's Evotec is to provide a broad range of pharmaceutical
discovery and chemical development services to Procter & Gamble
Pharmaceuticals in a lift for its outsourcing business.
German biotech company Evotec OAI posted decreased third quarterly
revenues of €16.1 million, down 26 per cent compared to 2003.
Evotec's performance reflects the difficult operating environment
for companies supplying drug discovery...
German biotech company Evotec OAI boosted its second quarter
revenues by 18 per cent to €17 million, despite the difficult
operating environment for companies supplying drug discovery
technologies, continuing its recovery from a weak...
Germany's Evotec recording a loss in the first quarter of 2004 due
in part, to what it said was a difficult operating environment for
companies supplying drug discovery technologies.
The company Evotec OAI, a drug discovery and development solution
provider to the pharmaceutical and biotechnology industries has
announced the successful expansion of their in vitro and in silico
ADMET (Adsorption, Distribution,...
Evotec OAI once again defied the difficult environment for drug
discovery technology companies with a 20 per cent hike in
nine-month revenues to €56.7 million. Growth was driven by the
firm's ultra high-throughput screening collaboration...
